RECURRENT PROSTATE CANCER
Clinical trials for RECURRENT PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new RECURRENT PROSTATE CANCER trials appear
Sign up with your email to follow new studies for RECURRENT PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental DNA vaccine aims to train immune system against prostate cancer
⭐️ VACCINE ⭐️ Recruiting nowThis early-phase trial tests whether an experimental DNA vaccine (pTVG-HP) combined with the immunotherapy drug nivolumab and targeted radiation can help the immune system attack prostate cancer that has returned in a few spots. The study involves 14 men whose cancer has come bac…
Matched conditions: RECURRENT PROSTATE CANCER
Phase: PHASE1 • Sponsor: University of Wisconsin, Madison • Aim: ⭐️ VACCINE ⭐️
Last updated May 18, 2026 11:59 UTC
-
Second chance: targeted radiation zaps recurrent prostate cancer
Disease control Recruiting nowThis study tests a high-dose-rate brachytherapy (internal radiation) for men whose prostate cancer has returned after previous external beam radiation. About 30 participants will receive a targeted radiation implant to the area of recurrence, aiming to control the cancer while li…
Matched conditions: RECURRENT PROSTATE CANCER
Phase: NA • Sponsor: British Columbia Cancer Agency • Aim: Disease control
Last updated May 26, 2026 09:59 UTC
-
Veterans' prostate cancer trial: can PET-Guided therapy buy more time?
Disease control Recruiting nowThis study for veterans with prostate cancer that has returned in a few spots (1-10) tests whether adding PET-directed local therapy to standard hormone therapy can delay the cancer from becoming resistant to treatment. About 464 participants will be randomly assigned to standard…
Matched conditions: RECURRENT PROSTATE CANCER
Phase: PHASE2, PHASE3 • Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated May 26, 2026 09:56 UTC
-
Could a common fungus pill fight prostate cancer?
Disease control Recruiting nowThis study tests whether terbinafine, a widely used antifungal pill, can slow the rise of PSA levels in men whose prostate cancer has returned after initial treatment. The trial enrolls 42 men with biochemical recurrence but no visible tumors on scans. The goal is to see if this …
Matched conditions: RECURRENT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Swiss Cancer Institute • Aim: Disease control
Last updated May 26, 2026 09:35 UTC
-
New hope for men with returning prostate cancer: drug combo aims to delay PSA rise
Disease control Recruiting nowThis study tests whether adding an injected drug (PDS01ADC) to a daily pill (enzalutamide) can better control prostate cancer that has returned after initial treatment. About 65 men will receive either enzalutamide alone or both drugs for 3 months, with possible extra treatment. …
Matched conditions: RECURRENT PROSTATE CANCER
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
New trial aims to Fine-Tune prostate cancer treatment timing
Disease control Recruiting nowThis study looks at whether giving radiation alone or with hormone therapy works better for men whose prostate cancer has returned and spread. It also tests if adding pelvic radiation helps stop further spread. About 532 men with recurrent, hormone-sensitive prostate cancer will …
Matched conditions: RECURRENT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 22, 2026 14:01 UTC
-
New laser treatment aims to control recurrent prostate cancer
Disease control Recruiting nowThis study tests a new treatment for men whose prostate cancer has come back after radiation therapy. The treatment uses lasers and a light-sensitive drug to destroy cancer cells while sparing healthy tissue. The goal is to see if it is safe and effective, and to find the best do…
Matched conditions: RECURRENT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: SpectraCure AB • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
New scan may catch hidden prostate cancer spread earlier
Knowledge-focused Recruiting nowThis study looks at 60 men with prostate cancer who had a high-risk genetic test (Decipher score >0.45). They will get a special PET scan (PSMA-PET) about 2 years after their first treatment to see if the cancer has spread. The goal is to learn how well the genetic test predicts …
Matched conditions: RECURRENT PROSTATE CANCER
Phase: PHASE2, PHASE3 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Knowledge-focused
Last updated May 26, 2026 10:03 UTC